Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2004



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

New Advances in Drug Discovery (F2)


Organizer(s) Christine M. Debouck, Joshua Boger and Paul A. Bartlett
March 21—26, 2004
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 21, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 21, 2004

Sponsored by ICOS Corporation

Summary of Meeting:
This Keystone Symposium is intended to bring together a multidisciplinary cross-section of scientists to openly discuss the most exciting recent advances in industry and academia in areas related to drug discovery and development. The completion of the human genome provides unique opportunities to enhance drug discovery through the utilization of sequence information, as well as of application of new tools to elucidate gene function in health and disease. In addition, a variety of novel technologies impacting chemistry and pharmacology promise to improve the speed and success rate of drug discovery and development. The meeting will focus on success stories in drug discovery, as well as highlight the impact of new technologies. Sessions will cover drug candidates in advanced clinical development; technology breakthroughs impacting the early stages of drug discovery; novel approaches for target validation; in vivo imaging technologies; new therapeutic target classes; initiatives influencing what compounds to make to increase development success rate; and, new strategies for clinical evaluation of drug candidates.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 21

15:00—19:00
Registration

Shavano Peak Foyer
18:15—19:15
Refreshments

Shavano Peak Foyer
19:15—19:30
Orientation

Red Cloud Peak
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Christine M. Debouck, Ardennes Biosciences LLC, USA

P. Roy Vagelos, Merck & Co., Inc., USA
The Basis of Drug Discovery, Past and Future


MONDAY, MARCH 22

07:00—08:00
Breakfast

Crestone Peak 1-4
08:00—11:00
Drug Candidates in Clinical Development
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Ron L. Magolda, Wyeth Research, USA

Colin H. Macphee, GlaxoSmithKline, USA
Lipoprotein-Associated Phospholipase A2 as a New Mediator of Coronary Artery Disease

John L. Ryan, AVEO Pharmaceuticals, Inc., USA
A Different Approach to Early Clinical Trials

John C.R. Randle, Vertex Pharmaceuticals Incorporated, USA
ICE Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases

Julian Adams, Vedantra Pharmaceuticals, Inc., USA
VELCADE™ (Bortezomib): A Proteasome Inhibitor for Cancer Therapy

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Crestone Peak 1-4
13:00—22:00
Poster Viewing

Crestone Peak 1-4
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Technology Breakthroughs Impacting the Early Stages of Drug Discovery. Session Sponsored in part by Iconix Pharmaceuticals, Inc.
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Leslie J. Browne, Senesco Technologies, Inc., USA

Paul Negulescu, Vertex Pharmaceuticals (San Diego) LLC, USA
High-Throughput Assays of Ion Channel Function

Gino B. Poulin, University of Manchester, UK
Genome-Wide RNAi Screens for Transcriptional Regulators in C. elegans

Anne E. Carpenter, Broad Institute of Harvard and MIT, USA
Cell-Based Microarrays

19:00—20:00
Social Hour

Crestone Peak 1-4
19:30—22:00
Poster Session 1: Target Validation and Screens

Crestone Peak 1-4

TUESDAY, MARCH 23

07:00—08:00
Breakfast

Crestone Peak 1-4
08:00—11:00
Target Validation: New or Integrated Approaches
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Christine M. Debouck, Ardennes Biosciences LLC, USA

Andrew Hopkins, University of Dundee, UK
The Pros and Cons of Traditional Target Classes (The Druggable Genome)

Kevan M. Shokat, University of California, San Francisco, USA
Forward and Reverse Chemical Genetics: New Tools for Target Discovery and Target Validation

Caretha L. Creasy, GlaxoSmithKline Pharmaceuticals, USA
Exploiting Invertebrate Genetics for Target Validation

Helmuth H. van Es, ModiQuest B.V., Netherlands
Biology Driven Target Discovery with Arrayed Adenoviral siRNA Libraries

09:20—09:40
Coffee Break

Shavano Peak Foyer
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Imaging Technologies
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Dean R. Artis†, Elan, USA

Markus Rudin, Universität Zürich, Switzerland
Small Animal Imaging in Drug Discovery: Disease Phenotyping, Therapy Evaluation and Biomarker Development

Paul M. Thompson, University of California, Los Angeles, USA
4D Mapping of Brain Changes in Alzheimer's and Schizophrenia: New Strategies for Drug Assessment

18:30—20:00
Social Hour

Crestone Peak 1-4
20:00—22:00
Panel Discussion: How are New R&D Structures and Processes Impacting the Success Rate?

Red Cloud Peak
* Joshua Boger, Vertex Pharmaceuticals Incorporated, USA


WEDNESDAY, MARCH 24

07:00—08:00
Breakfast

Crestone Peak 1-4
08:00—11:00
New Target Classes
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Paul A. Bartlett, University of California, Berkeley, USA

Carolyn R. Bertozzi, Stanford University, USA
New Therapeutic Targets in Sulfation Pathways

Jennifer A. Doudna, HHMI/University of California, Berkeley, USA
From Ribozymes to Ribosomes: RNA as a Drug Target

Peter B. Reiner, University of British Columbia, Canada
ABC Transporters: Under Appreciated Gems of Drug Discovery

Franz Kricek, Novartis Forschungsinstitut, Austria
Fc Receptor Stalk Regions: Novel Targets for Receptor Antagonists?

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Crestone Peak 1-4
13:00—22:00
Poster Viewing

Crestone Peak 1-4
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
What Drugs to Make?
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Randall W. Hungate, Amgen Inc., USA

Brian K. Shoichet, University of California, San Francisco, USA
A Specific Mechanism for Non-Specific Hits in Drug Discovery

Thomas Ulich, Xenetic Biosciences plc, UK
RNAi: Biology to Drugs

Leslie J. Browne, Senesco Technologies, Inc., USA
Removing Barriers to Efficient Drug Discovery through Chemogenomics

19:00—20:00
Social Hour

Crestone Peak 1-4
19:30—22:00
Poster Session 2: Small Molecules, Computation

Crestone Peak 1-4

THURSDAY, MARCH 25

07:00—08:00
Breakfast

Crestone Peak 1-4
08:00—11:00
Clinical Trials Design. Session Sponsored by Vertex Pharmaceuticals Incorporated.
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Michael K. Trower, GlaxoSmithKline, UK

Steven A. Carr, Broad Institute, USA
Biomarker Discovery by Proteomics and its Role in Drug and Diagnostic Development

David Mauro, Checkmate Pharmaceuticals, USA
Pharmacogenomic Applications in Clinical Development

Aidan Power, Pfizer Inc., USA
Clinical Trial Design for Antidepressants: A Pharmacogenomics Approach

Colin Garner, , UK
Human Phase 0 (Microdosing): Big Physics, Small Doses to Obtain Early Human PK and PD Data

09:20—09:40
Coffee Break

Shavano Peak Foyer
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—18:30
Late Breaking News
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Peter R. Young, Celera, Inc, USA

Linda S. Kaltenbach, Duke University, USA
A System-Scale Yeast-Based Process Integrating Proteomic and Small Molecule Discovery

Mikkel D. Lundorf, Nuevolution A/S, Denmark
Chemetics ™ - DNA-Encoded Synthesis and Selection of Drug-Like Small Molecules

Ron L. Magolda, Wyeth Research, USA
Selective Estrogen Receptor-beta Agonists are Potent Anti-Inflammatory Agents

18:30—19:30
Closing Address
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Joshua Boger, Vertex Pharmaceuticals Incorporated, USA

Paul A. Bartlett, University of California, Berkeley, USA
Peptodomimetics and Proteomimetics: Exercise in Conformational Control

19:30—20:30
Social Hour

Crestone Peak 1-4
20:30—23:00
Entertainment

Crestone Peak 1-4

FRIDAY, MARCH 26

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge additional support for this conference from:


Cell Signaling Technology, Inc.
Iconix Biosciences, Inc.
ICOS Corporation Vertex Pharmaceuticals Incorporated

Cell Signaling Technology, Inc.
 

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676